Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 31;56(4):301-314.
doi: 10.5045/br.2021.2021187.

Twenty-year incidence trend of hematologic malignancies in the Republic of Korea: 1999-2018

Won-Ju Park  1   2   3 , Joo-Heon Park  4 , Seunghyeon Cho  1 , Myung Geun Shin  4
Affiliations

Twenty-year incidence trend of hematologic malignancies in the Republic of Korea: 1999-2018

Won-Ju Park et al. Blood Res. .

Abstract

Background: In this study, we presented the national cancer statistics on the incidence of hematologic malignancies in the Republic of Korea (ROK) over a period of 20 years, from 1999 to 2018.

Methods: We obtained data on the incidence of hematologic malignancies using the Korean Statistical Information Service (KOSIS). For each hematologic malignancy, the number of cases, crude incidence rate, and age-standardized incidence rate were calculated, and the statistical trends were confirmed by Poisson regression and Joinpoint regression analysis.

Results: All the investigated hematologic malignancies showed a statistically significant increase in incidence over 20 years. The 20-year trend of the age-standardized incidence rate was as follows: non-Hodgkin lymphoma [average annual percent change (AAPC)=2.26%, P-trend <0.05], leukemia (AAPC=0.94%, P-trend <0.05), myeloid leukemia (AAPC=1.44%, P-trend <0.05), multiple myeloma (AAPC=3.05%, P-trend <0.05), myeloproliferative disorders (AAPC=9.87%, P-trend <0.05), myelodysplastic syndrome (AAPC=7.59%, P-trend <0.05), malignant immunoproliferative diseases (AAPC=11.82%, P-trend <0.05), lymphoid leukemia (AAPC=2.21%, P-trend <0.05), and Hodgkin lymphoma (AAPC=4.04%, P<0.05).

Conclusion: It was confirmed that the incidence of hematologic malignancies has increased significantly in the ROK over the past 20 years. This study can be used as foundational data source for future studies. In addition, it can aid in the necessary actions of predicting future incidences and establishing future healthcare policies.

Keywords: Epidemiology; Hematologic neoplasms; Neoplasms; Registries; Statistics.

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Annual incidence of non-Hodgkin lymphoma in the Republic of Korea. Number of non-Hodgkin lymphoma cases (A). Crude and age-standardized incidence rate of non-Hodgkin lymphoma per million using the 2000 Korean standard population (B). a)Comparing 1999 and 2018. b)Average annual percent change by Joinpoint regression analysis. c)Incidence rate ratio per year from 1999 to 2018 as calculated by Poisson regression. Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CI, confidence interval; CIR, crude incidence rate; IRR, incidence rate ratio.
Fig. 2
Fig. 2
Annual incidence of leukemia in the Republic of Korea. Number of leukemia cases (A). Crude and age-standardized incidence rate of leukemia per million using the 2000 Korean standard population (B). a)Comparing to 1999 and 2018. b)Average annual percent change by Joinpoint regression analysis. c)Incidence rate ratio per year from 1999 to 2018 as calculated by Poisson regression. Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CI, confidence interval; CIR, crude incidence rate; IRR, incidence rate ratio.
Fig. 3
Fig. 3
Annual incidence of myeloid leukemia in the Republic of Korea. Number of myeloid leukemia cases (A). Crude and age-standardized incidence rate of myeloid leukemia per million using the 2000 Korean standard population (B). a)Comparing 1999 and 2018. b)Average annual percent change by Joinpoint regression analysis. c)Incidence rate ratio per year from 1999 to 2018 as calculated by Poisson regression. Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CI, confidence interval; CIR, crude incidence rate; IRR, incidence rate ratio.
Fig. 4
Fig. 4
Annual incidence of multiple myeloma in the Republic of Korea. Number of multiple myeloma cases (A). Crude and age-standardized incidence rate of multiple myeloma per million using the 2000 Korean standard population (B). a)Comparing 1999 and 2018. b)Average annual percent change by Joinpoint regression analysis. c)Incidence rate ratio per year from 1999 to 2018 as calculated by Poisson regression. Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CI, confidence interval; CIR, crude incidence rate; IRR, incidence rate ratio.
Fig. 5
Fig. 5
Annual incidence of myeloproliferative disorders in the Republic of Korea. Number of myeloproliferative disorders cases (A). Crude and age-standardized incidence rate of myeloproliferative disorders per million using the 2000 Korean standard population (B). a)Comparing 1999 and 2018. b)Average annual percent change by Joinpoint regression analysis. c)Incidence rate ratio per year from 1999 to 2018 as calculated by Poisson regression. Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CI, confidence interval; CIR, crude incidence rate; IRR, incidence rate ratio.
Fig. 6
Fig. 6
Annual incidence of myelodysplastic syndrome in the Republic of Korea. Number of myelodysplastic syndrome cases (A). Crude and age-standardized incidence rate of myelodysplastic syndrome per million using the 2000 Korean standard population (B). a)Comparing 1999 and 2018. b)Average annual percent change by Joinpoint regression analysis. c)Incidence rate ratio per year from 1999 to 2018 as calculated by Poisson regression. Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CI, confidence interval; CIR, crude incidence rate; IRR, incidence rate ratio.
Fig. 7
Fig. 7
Annual incidence of malignant immunoproliferative diseases in the Republic of Korea. Number of malignant immunoproliferative diseases cases (A). Crude and age-standardized incidence rate of malignant immunoproliferative diseases per million using the 2000 Korean standard population (B). a)Comparing 1999 and 2018. b)Average annual percent change by Joinpoint regression analysis. c)Incidence rate ratio per year from 1999 to 2018 as calculated by Poisson regression. Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CI, confidence interval; CIR, crude incidence rate; IRR, incidence rate ratio.
Fig. 8
Fig. 8
Annual incidence of lymphoid leukemia in the Republic of Korea. Number of lymphoid leukemia cases (A). Crude and age-standardized incidence rate of lymphoid leukemia per million using the 2000 Korean standard population (B). a)Comparing 1999 and 2018. b)Average annual percent change by Joinpoint regression analysis. c)Incidence rate ratio per year from 1999 to 2018 as calculated by Poisson regression. Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CI, confidence interval; CIR, crude incidence rate; IRR, incidence rate ratio.
Fig. 9
Fig. 9
Annual incidence of Hodgkin lymphoma in the Republic of Korea. Number of Hodgkin lymphoma cases (A). Crude and age-standardized incidence rate of Hodgkin lymphoma per million using the 2000 Korean standard population (B). a)Comparing 1999 and 2018. b)Average annual percent change by Joinpoint regression analysis. c)Incidence rate ratio per year from 1999 to 2018 as calculated by Poisson regression. Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CI, confidence interval; CIR, crude incidence rate; IRR, incidence rate ratio.
See this image and copyright information in PMC

References

    1. Statistics Korea, author. Cause of death statistics in 2019. Statistics Korea; Daejeon, Korea: 2020. [Accessed August 31, 2021]. at http://kostat.go.kr/portal/eng/pressReleases/8/10/index.board .
    1. Hong S, Won YJ, Lee JJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021;53:301–5. doi: 10.4143/crt.2021.291. - DOI - PMC - PubMed
    1. Korean Statistical Information System (KOSIS), author Statistical database. Statistics Korea; Daejeon, Korea: 2021. [Accessed August 31, 2021]. at https://kosis.kr/eng .
    1. Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology. Third ed. World Health Organization; Geneva, Switzerland: 2013. [Accessed August 31, 2021]. at https://apps.who.int/iris/bitstream/handle/10665/96612/9789241548496_eng... .
    1. National Cancer Center (NCC), author Annual report of cancer statistics in Korea in 2018. NCC; Goyang-si, Korea: 2021. [Accessed August 31, 2021]. at https://ncc.re.kr/cancerStatsView.ncc?bbsnum=558&searchKey=total&searchV... .